MOGLING BIO INC

Biotech · Private

CASIN, a small molecule Cdc42-activity inhibitor therapeutic for attenuating hematopoietic stem cell aging

Grants
$300K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Pharmacological rejuvenation of human hematopoietic stem cells$299,781
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1921WILD MICROBES CO——
1922Onramp Invest, Inc.—$5.0M
1923Immunocore——
1924MOGLING BIO INC——
1925Arch Innotek, LLC——
1926GENELANCET BIOSCIENCES INC——
1927CODA Biotherapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • New Compounds For Medical Useapplication
  • Compounds For Medical Useapplication
  • Compounds For Medical Useapplication
  • Compounds For Medical Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.